Antithrombotic Therapy of Acute Stroke: Thrombolytic Agents

• References

• 1 Sussman BJ, Fitch TSP. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 1958; 167: 1705-1709
• 2 del ZoppoGJ, Zeumer H, Harker LA. Thrombolytic therapy in acute stroke:Possibilities and hazards. Stroke 1986; 17: 595-607
• 3 Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989; 91: 311-321
• 4 del ZoppoGJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee Jr R, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, otis SM. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86
• 5 Fieschi C, Bozzao L. Transient embolic occlusion of the middle cerebral and internal carotid arteries in cerebral apoplexy. J Neurol Neurosurg Psychiatry 1969; 32: 236-240
• 6 Solis oJ, Roberson GR, Taveras JM, Mohr J, Pessin MS. Cerebral angiography in acute cerebral infarction. Revist Interam Radiol 1977; 02: 19-25
• 7 Irino T, Taneda M, Minami T. Angiographic manifestations in post-recanalized cerebral infarction. Neurology 1977; 27: 471-475
• 8 Yamaguchi T, Minematsu K, Choki J, Ikeda M. Clinical and neuroradiological analysis of thrombotic and embolic cerebral infarction. Jpn Circ J 1984; 48: 50-58
• 9 Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-982
• 10 Yamaguchi T. Intravenous tissue plasminogen activator in acute thromboembolic stroke:A placebo-controlled, double-blind trial. In: Thrombolytic Therapy in Acute Ischemic Stroke II. del ZoppoGJ, Mori E, Hacke W. eds Springer-Verlag; Heidelberg: 1993. pp 59-65
• 11 von KummerR, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery. Stroke 1992; 23: 646-652
• 12 Baron JC, von KummerR, del ZoppoGJ. Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window (Editorial). Stroke 1995; 26: 2219-2221
• 13 Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Mariwald M, Rohlfc M, Suhr H, Fiehn W, Becher H, Hacke W. Recent infection as a risk factor for cerebrovascular ischemia. Stroke 1995; 26: 373-379
• 14 Mori E. Fibrinolytic recanalization therapy in acute cerebrovascular thromboembolism. In: Thrombolytic Therapy in Acute Ischemic Stroke. Hacke W, del ZoppoGJ, Hirschberg M. eds Springer-Verlag; Heidelberg: 1991. pp 137-46
• 15 del ZoppoGJ, Ferbert A, Otis S, Briickmann H, Hacke W, Zyroff J, Harker LA, Zeumer H. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke:A pilot study. Stroke 1988; 19: 307-313
• 16 Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988; 19: 802-812
• 17 Astrup J, Symon L, Branston NM, Lassen N. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 1977; 08: 51-57
• 18 Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia—The ischemic penumbra. Stroke 1981; 12 (06) 723-725
• 19 Skyhoj-Olsen T, Larsen B, Herring M, Skawer EB, Lassen NA. Blood flow and vascular reactivity in collateral perfused brain tissue:Evidence of an ischemic penumbra. Stroke 1983; 14: 332-341
• 20 Aldrich MS, Sherman SA, Greenberg HS. Cerebrovascular complications of streptokinase infusion. JAMA 1985; 253: 1777-1779
• 21 Fletcher AP, Alkjaersig N, Lewis M, Tulevski V, Davies A, Brooks JE, Mardin WB, Landau WM, Raichle ME. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 07: 135-142
• 22 Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Bessom G, Leys D, Amarenio P, Bogart M. for the MAST Group Termination of trial of streptokinase in severe acute ischemic stroke (Letter). Lancet 1995; 345: 578-579
• 23 The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145-150
• 24 Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EC, Tuck RR. Trials of streptokinase in severe acute ischaemic stroke. Lancet 1995; 345: 578-579
• 25 Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von KummerR, Boysen G, Bluhmki E, Hoxter G, Mahagne M-H, Hennerici M. for the ECASS Study Group Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025
• 26 The National Institutes of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
• 27 Pessin MS, del ZoppoGJ, Estol CJ. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990; 13: 271-289
• 28 Pessin MS, Teal PA, Caplan LR. Hemorrhagic infarction: Guilt by association. AJNR 1991; 12: 1123-1126
• 29 Okada Y, Yamaguchi T, Minematsu K, Miyashita T, Sawada T, Sadoshima S, Fujishima M, Omae T. Hemorrhagic transformation in cerebral embolism. Stroke 1989; 20: 598-603
• 30 Drake ME, Shin C. Conversion of ischemic to hemorrhagic infarction by anticoagulant administration. Report of two cases with evidence from serial computed tomographic brain scans. Arch Neurol 1983; 40: 44-46
• 31 Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Neurology 1963; 13: 927-937
• 32 Babikian VL, Kase CS, Pessin MS, Norrving B, Gorelick PB. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke 1989; 29: 1500-1503
• 33 Furlan AJ, Cavalier SJ, Hobbs RE, Weinstein MA, Modic MI. Hemorrhage and anticoagulation after nonseptic embolic brain infarction. Neurology 1982; 32: 280-282
• 34 Koller RL. Recurrent embolic cerebral infarction and anticoagulation. Neurology 1982; 32: 283-285
• 35 Mori E, Yoneda Y, Ohkawa S, Yoshida T, Ohsumi Y, Tabuchi M, Yamadori A, Kitano K, Tsutsumi A. Double-blind placebo-controlled trial of intravenous recombinant tissue plasminogen activator (rt-PA) in acute carotid stroke. Neurology 1991; 41 (Suppl. 01) 347
• 36 Ogata J, Yutani C, Imakita M, Ishibashi-Ueda H, Saku Y, Minematsu K, Sawada T, Yamaguchi T. Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. Stroke 1989; 20: 876-883
• 37 Fisher CM, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 1951; 10: 92-94
• 38 Fisher CM, Adams RD. Observations on brain embolism with special reference to hemorrhage infarction. In: The Heart and Stroke. Exploring Mutual Cerebrovascular and Cardiovascular Issues. Furlan AJ. ed Springer-Verlag; New York: 1987. pp 17-36
• 39 Levy DE, Brott TG, Haley Jr EC, Marler JR, Sheppard GL, Barsan W, Broderick JP. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25: 291-297
• 40 Ueda T, Hatakeyama T, Kumon Y, Sakaki S, Uraoka T. Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT. Stroke 1994; 25: 298-303
• 41 Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke—Background and study protocol. Stroke 1985; 16: 885-890
• 42 Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957; 02: 200-215
• 43 Loewen SC, Anderson BA. Reliability of the modified motor assessment scale and the Barthel index. Phys Ther 1988; 68: 1077-1081
• 44 Mahoney FJ, Barthel DW. Functional evaluation. The Barthel index. Md Med J 1965; 14: 61-65
• 45 Coté R, Hachinski VC, Shurtell BL, Norris JW, Wolfson C. The Canadian Neurological Scale: A preliminary study in acute stroke. Stroke 1986; 17: 731-737
• 46 Clarke RL, Cliffton EE. The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents. Am J Cardiol 1960; 30: 546-551
• 47 Herndon RM, Meyer JS, Johnson JF, Landers J. Treatment of cerebrovascular thrombosis with fibrinolysin. Preliminary report. Am J Cardiol 1960; 30: 540-545
• 48 Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 1964; 189: 373
• 49 Hanaway J, Torack R, Fletcher AP, Landau WM. Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke. Stroke 1976; 7: 143-146
• 50 NIH Consensus Conference. Thrombolytic therapy in treatment. Br Med J 1980; 280: 1585-1587
• 51 Abe T, Kazawa M, Naito I, Kanaya H, Machino R, Igata A, Tazaki Y, Kameyama M, Goto F, Maezawa H, Watanabe H, Urushiyama K, Togi H, Sakuragawa N, Atarashi J, Kito S, Araki OnoderaH, Otomo E, Ogawa N. Clinical effect of urokinase (60,000 units/day) on cerebral infarction — Comparative study by means of multiple center double blind test. Blood Vessel 1981; 12: 342-358
• 52 Abe T, Kazama M, Naito I, Ueda M, Tanaka T, Higuchi H, Saso S, Kariyone S, Yoshimura M, Maekawa T, Morimatsu M, Moriyasu N, Takagi S, Maezawa H, Kase M, Kuwana N, Odakura T, Takasu K, Sugawara Y, Takahashi A, Okubo M, Ijichi H, Yamamoto S, Kikuchi H, Kito S, Tokito S, Iwasaki Y. Clinical evaluation for efficacy of tissue culture urokinase (TCUK) on cerebral thrombosis by means of multicenter double-blind study. Blood Vessel 1981; 12: 321-341
• 53 Atarashi J, Otomo E, Araki G, Itoh E, Togi H, Matsuda T. Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis: Multi-center double-blind study in comparison with placebo. Clin Eval 1985; 13: 659-709
• 54 Otomo E, Araki G, Itoh E, Tohgi H, Matuda T, Atarashi J. Clinical efficacy of urokinase in the treatment of cerebral thrombosis. Clin Eval 1985; 13: 711-751
• 55 Otomo E, Tohgi H, Hirai S, Terashi A, Takakura K, Araki G, Ito MatsudaT, Sawada T, Fujishine M, Ogawa Y. Clinical efficacy of AK-124 (tissue plasminogen activator) in the treatment of cerebral thrombosis:Study by means of multi-center double blind comparison with urokinase. Yakuri To Chiryo 1988; 16: 3775-3821
• 56 Abe T, Machii K, Kajiwara N, Kawai C, Kanmatsuse K, Kanbara NobuyoshiM, Yamaguchi T, Osada H, Kawada H, Matsuo O. Clinical usefulness of intravenous application of SM-9527 (duteplase; t-PA) in acute myocardial infarction: A multicentered, double-blind comparative study with intravenous administration of urokinase. Clin Eval 1989; 17: 485-515
• 57 Zeumer H, Freitag HJ, Grzyka U, Neunzig HP. Local intra-arterial fibrinolysis in acute vertebrobasilar occlusion. Technical developments and recent results. Neuroradiology 1989; 31: 336-340
• 58 Zeumer H. Survey of progress:Vascular recanalizing techniques in interventional neuroradiology. J Neurol 1985; 231: 287-294
• 59 Theron J, Courtheoux P, Casaseo A, Alachkar F, Notari F, Garen MaizaD, Maiza D. Local intra-arterial fibrinolysis in the carotid territory. AJNR 1989; 10: 753-765
• 60 Matsumoto K, Satoh K. Topical intraarterial urokinase infusion for acute stroke. In: Thrombolytic Therapy in Acute Ischemic Stroke. Hacke W, del ZoppoGJ, Hirschberg M. eds Springer-Verlag; Heidelberg: 1991. pp 207-212
• 61 Hacke W, Zeumer H, Ferbert A, Brückmann H, del ZoppoGJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216-1222
• 62 Möbius E, Berg-Dammer E, Kühne D, Nahser HC. Local thrombolytic therapy in acute basilar artery occlusion: Experience with 18 patients. In: Thrombolytic Therapy in Acute Ischemic Stroke. Hacke W, del ZoppoGJ, Hirschberg M. eds Springer-Verlag; Heidelberg: 1991. pp 213-215
• 63 Zeumer H, Freitag H-J, Zarella F, Thie A, Arnig C. Local intra-arterial fibrinolytic therapy in patients with stroke: Urokinase vs recombinant tissue plasminogen activator (rt-PA). Neuroradiology 1993; 35: 159-162
• 64 Freitag H-J, Zeumer H, Knospe V. Acute central retinal artery occlusion and the role of thrombolysis. In: Thrombolytic Therapy in Acute Ischemic Stroke II. del ZoppoGJ, Mori E, Hacke W. eds Springer-Verlag; Heidelberg: 1993. pp 103-105
• 65 Ohtaki M, Shinya T, Yamamura A, Minamida Y. et al Local fibrinolytic therapy using superselective catheterization for patients with acute cerebral embolism within 10 hours. In: Microcirculatory Stasis in the Brain. Tomita M, Mchedlishvili A, Rosenblum W, Heiss W-D, Fukuuchi Y. eds. Elsevier Science; Amsterdam: 1993. pp 539-545
• 66 Higashida RT, Halbach VV, Barnwell SL, Dowd CF, Hieshima GB. Thrombolytic therapy in acute stroke. J Endovasc Surg 1994; 01: 04-15
• 67 Barnwell SL, Clark WM, Nguyen TT, O’Neill OR, Wynn ML, Coull BM. Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR 1994; 15: 1817-1822
• 68 Jansen O, von KummerR, Forsting M, Hacke W, Sartor K. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. AJNR 1995; 16: 1977-1986
• 69 von KummerR, Forsting M, Sartor K, Hacke W. Intravenous recombinant tissue plasminogen activator in acute stroke. In: Thrombolytic Therapy in Acute Ischemic Stroke. Hacke W, del ZoppoGJ, Hirschberg M. eds Springer; Heidelberg: 1991. pp 161-167
• 70 Yamaguchi T. Intravenous rt-PA in acute embolic stroke. In: Thrombolytic Therapy in Acute Ischemic Stroke. Hacke W, del ZoppoGJ, Hirschberg M. eds Springer-Verlag; Heidelberg: 1991. pp 168-174
• 71 Yamaguchi T, Kikuchi H, Hayakawa T. for the Japanese Thrombolysis Study Group Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: A randomized, double-blind, dose-comparison study of duteplase. In: Thrombolysis in Acute Ischemic Stroke III. Yamaguchi T, Mori E, Minematsu K, del ZoppoGJ. eds Springer-Verlag; Tokyo: 1995. pp 223-229
• 72 Yamaguchi T, Hayakawa T, Kiuchi H. Intravenous tissue plasminiogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993; 03: 269-272
• 73 Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination.of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509-1514
• 74 Tognoni G, Roncaglioni MC. Dissent:An alternative interpretation of MAST-I. Lancet 1995; 346: 1515
• 75 Gruppo Italiano Per Lo Studio Della Streptochinasi Nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 01: 397-401
• 76 Gruppo Italiano Per Lo Studio Della Streptochinasi Nell’Infarto Miocardico (GISSI). GISSI-2:A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71
• 77 Haley Jr EC, Levy DE, Brott TG, Sheppard GL, Wong MCW, Kongable GL, Tomer JC, Marler JR. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-645
• 78 Haley Jr EC, Brott TG, Sheppard GL, Barsan W, Broderick J, Marler JR, Kongable GL, Spilker J, Massey S, Hansen CA, Tomer JC. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993; 24: 1000-1004
• 79 Brott TG, Haley Jr EC, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, Marler JR. Urgent therapy for stroke. Part I. Pilot study of tissue plaminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640
• 80 Nenci GG, Gresele P, Taramelli M, Agnelli G, Signorini E. Thrombolytic therapy for thromboembolism of vertebrobasilar artery. Angiology 1983; 34: 561-571
• 81 Kwaan HC. Thromboembolic disorders of the eye. In: Thrombolytic Therapy. Comerota AC. ed Grune and Stratton; Orlando: 1988. pp 153-163
• 82 Schmidt D, Schumacher M, Wakhloo AK. Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol 1992; 113: 429-434
• 83 del ZoppoGJ, Higashida RT, Furlan AJ, Pessin MS, Gent M, Driscoll RM. and the PROACT Investigators The Prolyse in Acute Cerebral Thromboembolism Trial (PROACT): Results of 6 mg dose tier. Stroke 1996; 27: 164 (Abstract)